GSK Follows Oncology Rivals’ Playbook in Search of Growth

GSK Plc is planning five simultaneous late-stage trials for a cancer drug it hopes will be a blockbuster, as new Chief Executive Officer Luke Miels tries to revitalize a company not known for its risk-taking.

Miels has been tasked with overhauling the British drugmaker, which has long struggled to allay investor fears about a lackluster pipeline. After little change over previous CEO Emma Walmsley’s almost nine-year tenure, GSK’s share price has risen close to 50% since Miels’ appointment was announced in September, outpacing large and medium-sized pharmaceutical companies in Europe.